RT Journal Article
T1 Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review.
A1 Prieto-Peña, Diana
A1 Bernabeu, Pilar
A1 Vela, Paloma
A1 Narvaez, Javier
A1 Fernandez-Lopez, Jesus C
A1 Freire-Gonzalez, Mercedes
A1 Gonzalez-Alvarez, Beatriz
A1 Solans-Laque, Roser
A1 Callejas-Rubio, Jose L
A1 Ortego, Norberto
A1 Fernandez-Diaz, Carlos
A1 Rubio, Esteban
A1 Garcia-Morillo, Salvador
A1 Minguez, Mauricio
A1 Fernandez-Carballido, Cristina
A1 de-Miguel, Eugenio
A1 Melchor, Sheila
A1 Salgado, Eva
A1 Bravo, Beatriz
A1 Romero-Yuste, Susana
A1 Salvatierra, Juan
A1 Hidalgo, Cristina
A1 Manrique, Sara
A1 Romero-Gomez, Carlos
A1 Moya, Patricia
A1 Alvarez-Rivas, Noelia
A1 Mendizabal, Javier
A1 Ortiz-Sanjuan, Francisco
A1 Perez-de-Pedro, Ivan
A1 Alonso-Valdivielso, Jose L
A1 Perez-Sanchez, Laura
A1 Roldan, Rosa
A1 Fernandez-Llanio, Nagore
A1 Gomez-de-la-Torre, Ricardo
A1 Suarez, Silvia
A1 Montesa-Cabrera, Maria Jesus
A1 Delgado-Sanchez, Monica
A1 Loricera, Javier
A1 Atienza-Mateo, Belwn
A1 Castañeda, Santos
A1 Gonzalez-Gay, Miguel A
A1 Blanco, Ricardo
K1 Caucasian
K1 Takayasu’s arteritis
K1 Tocilizumab
K1 Biological therapy
K1 cDMARDs
AB To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZCOMBO were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.
PB Sage Publications
SN 1759-720X
YR 2021
FD 2021-06-18
LK http://hdl.handle.net/10668/18141
UL http://hdl.handle.net/10668/18141
LA en
NO Prieto-Peña D, Bernabeu P, Vela P, Narváez J, Fernández-López JC, Freire-González M, et al. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. Ther Adv Musculoskelet Dis. 2021 Jun 18;13:1759720X211020917
DS RISalud
RD Aug 13, 2025